Blue Jet Healthcare IPO: Blue Jet Healthcare Limited's first public offering (IPO) began today. The book build issue will be offered for bidding until October 27th, 2023. This means that the Blue Jet Healthcare IPO application period runs from Wednesday to Friday this week. Blue Jet Healthcare IPO pricing has been set at $329 to $346 per equity share, with the public offering planned for listing on the BSE and NSE. Meanwhile, Blue Jet Healthcare Limited shares have already made their debut on the gray market. According to market experts, shares of Blue Jet Healthcare are currently available in the gray market at a premium of $85 per share.

Important Blue Jet Healthcare IPO Information

1] Blue Jet Healthcare IPO GMP: According to market observers, shares of Blue Jet Healthcare are currently available in the grey market at a premium of $85 per share.

2] Blue Jet Healthcare IPO date: The public offering will be offered for bidding from October 25th to October 27th, 2023.

3] Blue Jet Healthcare IPO price: The business has set the initial public offering price at $329 to $346 per equity share.

4] Blue Jet Healthcare IPO size: The business intends to raise 840.27 crore through its book build offer, which is entirely for sale (OFS).

5] Blue Jet Healthcare IPO lot size: Bidders will be able to apply for this issuance in lots, with each lot containing 43 company shares.

6] Blue Jet Healthcare IPO allotment date: The 1st of November 2023 is the most likely date for finalizing share distribution.

8] Blue Jet Healthcare IPO: The book build issue has been proposed for listing on the BSE and NSE.

9] Blue Jet Healthcare IPO listing date: The share listing is expected to take place on November 6, 2023.

10] Blue Jet Healthcare IPO review: According to a Choice Broking analysis, "BJHL is primarily a Contract Development and Manufacturing Organisation (CDMO), deriving approximately 75% of its revenue from CDMO operations." Its product profile is niche, and it has formed long-term relationships with its clients throughout the course of its operations. As a result, it is now able to generate approximately 70% of total business from long-term contracts with such clients. The company claimed substantial growth in the business during FY20-23, but rising raw material costs hampered profitability. Despite a threefold increase in net wealth, RoE was robust. BJHL will gain in the future from continuous demand for its products as well as lower/stabilizing raw material prices. Certain brownfield and greenfield additions are planned, which will increase installed capacity by about 50% over FY25E. So, the Blue Jet Healthcare IPO offers good growth potential and a comfortable valuation, and one can subscribe to this public offering."

Reliance Securities has also assigned the IPO the 'subscribe' label, citing, "BJHL is one of the innovative companies in niche categories with more than two decades of experience and has specialized chemistry capabilities; with dedicated R&D laboratories to offer various products in highly concentrated contrast media formulations." Going forward, management will pursue a sensible strategy of diversifying revenues, with a focus on exports and a high margin product mix. Increased expansion over the next two years to meet anticipated demand and leverage customer connections for pharma intermediates and API categories will raise earnings in the next few years. We suggest that you SUBSCRIBE to the issue.”